Ultragenyx Pharmaceutical
RARE
#4650
Rank
$2.05 B
Marketcap
$20.95
Share price
8.55%
Change (1 day)
-42.14%
Change (1 year)

Operating Margin for Ultragenyx Pharmaceutical (RARE)

Operating Margin as of April 2026 (TTM): -75.63%

According to Ultragenyx Pharmaceutical's latest financial reports and stock price the company's current Operating Margin is -75.63%. At the end of 2025 the company had an Operating Margin of -84.84%.

Operating Margin history for Ultragenyx Pharmaceutical from 2017 to 2025

Operating Margin at the end of each year

Year Operating Margin Change
2025-84.84%-16.2%
2024-101.25%-27.84%
2023-140.32%-27.35%
2022-193.14%49.83%
2021-128.91%88.48%
2020-68.39%-82.24%
2019-385.14%0.62%
2018-382.75%-96.86%
2017-12,187.52%-93.41%
2016-184,841.35%

Operating Margin for similar companies or competitors

Company Operating Margin Operating Margin differencediff. Country
Lexicon Pharmaceuticals
LXRX
-96.77% 27.95%๐Ÿ‡บ๐Ÿ‡ธ USA
Esperion Therapeutics
ESPR
-15.57%-79.41%๐Ÿ‡บ๐Ÿ‡ธ USA
Amicus Therapeutics
FOLD
0.03%-100.04%๐Ÿ‡บ๐Ÿ‡ธ USA
BioMarin Pharmaceutical
BMRN
14.97%-119.79%๐Ÿ‡บ๐Ÿ‡ธ USA

What is a company's Operating Margin?

The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.